Summary of the STEPS trial which will be a twitter spaces discussion
Regarding the Situation with…Social Media in General
Regarding the Situation with…Twitter, Bluesky, Social Media
We at #NephJC pride ourselves on bringing you the best in nephrology publications and innovations without commercial bias. As we’ve stated during many a donation drive, we are beholden to none but our followers and readers.
Having said that, we’ve noticed a trend since the death of Twitter (yes, it will always be Twitter to the real FOAMed illuminati). The diaspora of NephTwitter were scattered throughout the nephro-universe of social media, never quite finding a new home. Perhaps the downfall of the Nephrologians can be a plot line for the next Mandalorian season?? Many left the social media space altogether because of the division, politicization and plain BS of some of the algorithms (I for one don’t need to see EVERYTHING Elon posts). However, we still believe there is a need for our unique style of nephrology education. Jon Stewart- yes, the comedian- recently likened social media to smoking: an addictive, attention seeking habit that is generally recognized as not healthy for most people and that is likely to be regulated for teen and self-regulate by adults. He believed the antidote was more long-form, nuanced edu-tainment. So, it light of the changing landscape, we are going to focus more on our blogs, VAs, and podcasts and less on live discussions on Bluesky.
NephJC is nothing if not nimble, and we have never been afraid of change.
So, given the low attendance at live chats (no judgement) we’re changing to a summary thread (a new 10 posts) with provocative questions to answer, at your leisure. We hope this keeps the discussions going without the need to be on social media for prolonged periods or at a specific hour and day. These threads will be posted at the familiar 9pm EST every other Tuesday. This shorter form will also allow us to post on multiple sites, and hopefully we will be easily accessible to you where you chat with other nephrophiles. Feel free to reply, chat, tag people in conversations whenever and wherever you see a #NephJC post. The team will be around, but we won’t be actively ‘moderating’ a one hour chat.
Sincerely,
NephJC Leadership
PS: As always we love to hear from our audience. If you have suggestions, or a better way to reach more people, we are all ears. Heck, if we hear enough complaints we might even bring back the chats!😉
Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia
Live Blogging Trials from Conferences
Hiponatremia: El Resumen Visual
La hiponatremia es uno de los trastornos electrolíticos más frecuentes en pacientes hospitalizados y se asocia de manera consistente con peores desenlaces. Su corrección mejora los valores, pero ¿realmente mejora los desenlaces clínicos ?
Revisa el resumen visual por Brian Rifkin y el nuevo formato de #NephJC
Hyponatremia Correction: The Visual Abstract
Hyponatremia is one of the most common electrolyte disorders in hospitalized patients and is consistently linked to worse outcomes. Correcting sodium improves the numbers—but does it improve short-term clinical outcomes?
Check out Brian Rifkin VA and the new #NephJC format
NephJC Short: The Push Trial
NephJC Covers LBCTs at the World Congress
Announcing the NephJC Editorial Internship
Are you a curious, motivated nephrology fellow or early‑career faculty member with a passion for science communication? NephJC is inviting a small group of talented individuals to join our Editorial Internship Program and become part of the team that shapes how nephrology is discussed, illustrated, and shared online.
As an intern, you’ll help craft the bimonthly NephJC Journal Club, one of the most vibrant hubs for post‑publication peer review in nephrology, while developing your skills as an editor, writer, illustrator, or podcaster. We’re also planning to expand our Instagram presence this year, so creative voices with an eye for visual storytelling will have new opportunities to shine.
What this internship offers
Collaboration with an experienced, dynamic production team
Engagement with cutting‑edge nephrology research
Increased professional visibility within the global nephrology community
Take your passion for kidneys, curiosity, and community to the next level- join the NephJC Editorial Internship Program and help us keep the nephrology spirit alive across platforms, including a more active IG presence.
The 2026 NephJC Kidneys Award Winners
TenPosts Rilparencel phase 2
Can we move beyond slowing CKD to actually repairing the kidney? Here is the summary of the last #NephJC chat discussing Rilparencel, a renal autologous cell therapy (REACT) infusion, and its effect on eGFR slope.
Thread by Akshaya Jayachandran
Med-Mastodon is Over. Mastodon is still alive.
Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
REACT: El Resumen Visual
REACT aterriza a #NephJC
Esta vez analizamos rilparencel, una terapia celular renal autóloga inyectada directamente en la corteza renal para enlentecer la perdida de la función renal en nefropatía diabética y ERC avanzada.
¿Estamos ante una nueva era en la nefrología?
Revisa el resumen visual por Natalia Nombera y únete a la discusión en #NephJC.
REACT: The Visual Abstract
REACT has landed to NephJC.
This time we explore rilparencel, an autologous kidney cell therapy injected directly into the renal cortex to slow kidney function decline in DKD and advanced CKD.
Is this the future of regenerative nephrology?
Take a look at the Visual Abstract Natalia Nombera and join the conversation on #NephJC.
2026 #NephJCKidneys vote begins
After an extended nomination period, it is time to vote for your favorites. Like in the previous years, you will need to be a subscriber to the newsletter to be eligible to vote. By voting you let our content creators know how much they are contributing the the FOAMed goals of NephJC.
Just one week to vote!
The link to vote will be available in the newsletter.
Here is the final ballot:
Article of the Year
PISCES trial: link| NephJC summary| Freely Filtered episode
ACHIEVE trial- spironolactone in dialysis: link| NephJC summary| Freely Filtered episode
VALIANT trial - pegcetacoplan in C3GN : link| NephJC summary
ORIGIN3 trial- atacicept in IgAN: link| NephJC summary| Freely Filtered episode
Primary aldosteronism underdiagnosed: link| NephJC summary
ADPKD KDIGO guideline: link| NephJC summary| Freely Filtered episode
REGENCY trial:- obinutuzumab in lupus nephritis link| NephJC summary| Freely Filtered episode
Metformin in advanced CKD: link| NephJC summary| Freely Filtered episode
HiLo- high vs low phosphorus target in dialysis: link| NephJC summary
Engaged Scientist of the Year
Jonathan Barratt @IgAN_JBarratt
Jordy Cohen @jordybc.bsky.social
Charmaine Lok - PISCES
Daniel Edmonston @danieledmonston.bsky.social
Nathan Hellman Social Media Project of the Year
ISN social media team for Spaces
Indian society of nephrology - social media team
Roger Rodby for Renal Biopsy Cases
Sophia Ambruso for abckidney.com
Most Valuable Player
Milagros Flores @dramiliflores.bsky.social
Brian Rifkin @brianrifkin.bsky.social
Akshaya Jaychandran @nephromommy-akshu.bsky.social
Visual Abstract of the Year
ISN-GKHA interactive map: From data to dialogue by Denisse Arellano
Akshaya Jaychandran ACHIEVE trial
Husam Alzayer: incremental dialysis
Krithika Mohan: herb nephropathy
NephJC Social Justice Award
WHO kidney resolution and UN political declaration
World KIdney Day- Kidney health for all
Dialysis delay at what cost? Protein restriction as a distraction in the age of GDMT
2026 KDIGO Anemia Management Guidelines
KDIGO 2026 Anemia in CKD: The Visual Abstract
Anemia remains a central challenge in chronic kidney disease, influencing quality of life, cardiovascular risk, and clinical outcomes. The updated KDIGO 2026 guideline provides practical recommendations on iron management, ESAs, HIF-PHIs, and transfusion strategies, emphasizing individualized care and risk–benefit assessment.
Take a quick look at the VA by Michelle Fravel summarizing the key concepts and clinical take-home message
KDIGO 2026 Anemia en la ERC: El Resumen Visual
La anemia continúa siendo un reto clave en la enfermedad renal crónica, con impacto directo en la calidad de vida, el riesgo cardiovascular y los desenlaces clínicos. La actualización KDIGO 2026 ofrece recomendaciones prácticas sobre el manejo del hierro, el uso de AEEs, PHI-HIFs y estrategias de transfusión, con énfasis en una toma de decisiones individualizada basada en riesgo-beneficio.
Revisa el resumen visual realizado por Michelle Fravel , donde resume los mensajes clave y las principales perlas clínicas de la guía 2026.
